Original Articles

Retracted: Somatic Mutation in Immunoglobulin Gene Variable Region in Patients with Chronic Lymphoid Leukemia and its Influence on Patients' Prognosis in Iran

Abstract

Introduction: Chronic Lymphocytic Leukemia (CLL) is among the most prevalent blood cancers in people over the age of 40. In addition to clinical-pathologic staging and blood tests, another crucial prognostic factor of CLL is the immunoglobulin variable heavy chain mutation analysis. Finding the most prevalent mutation type and conducting a molecular analysis of it in the majority of the patients can contribute to identifying the disease pattern in a specific region or country. In the present study, we have used molecular detection methods in order to find the relationship between clinical pathologic findings and immunoglobulin heavy chain mutations in CLL patients in Iran.Material and methods: From 2009-2011, 26 patients with a suspected diagnosis of CLL were randomly selected from patients referred to Imam Khomeini Hospital. All patients underwent a clinical staging of the disease and had flow cytometric analysis performed on blood samples. The panels of cell surface markers used for the diagnosis of Chronic Lymphoid Leukemia include CD19, CD3, CD23, CD10 and CD5. The diagnosis confirmed a minimum of 20% positive expression of dual CD5 and CD19 markers. Genomic DNA was then extracted from the patients’ blood and IGVH mutation analysis was conducted with pGEM-T kit.Results: Patients were in an age range of 42 to 80, with their mean age being 62 (SE=1.87) and 73% of them being male. Their mean WBC count, lymphocytes percentage, average hemoglobin level and platelet count were, respectively, 56000/microliter, 85%, 12 gr/dl and 150000/microliter. According to their molecular analysis, 38.9% of patients were unmutated and 61.1% showed mutation in the variable heavy chain locus. The most common mutation had occurred in the IGVH3 allele (66.66%). The mean overall survival rate of patients, mutated and unmutated, was, respectively, 39 (95%CI 32, 46) and 31 (95%CI 26, 36) months (P=0.407).Benet stage had statistically meaningful relation to patients survival (p=0.02)Discussion: Similar to the findings of other studies, IGVH3 mutations were found to be prevalent by this study too. Although a correlation was found to exist between the patients’ survival and IGVH mutation, it was not statistically significant due to the limited number of the patients. We can conclude that clinical methods are still valuable in determining the prognosis of patients with CLL today.

Kokhaei P, Rezvany MR, Virving L, Choudhury A, Rabbani H, Oster- borg A, et al. Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL. Leukemia : official journal of the Leukemia Society of America, Leu- kemia Research Fund, UK. 2003 May;17(5):894-9. PubMed PMID: 12750703. Epub 2003/05/17. eng.

Herishanu Y, Polliack A. Chronic lymphocytic leukemia: A review of some new aspects of the biology, factors influencing prognosis and ther- apeutic options. Transfusion and Apheresis Science. 2005 2//;32(1):85- 97.

Tobin G, Thunberg U, Laurell A, Karlsson K, Aleskog A, Willand- er K, et al. Patients with chronic lymphocytic leukemia with mutated VH genes presenting with Binet stage B or C form a subgroup with a poor outcome. Haematologica. 2005 Apr;90(4):465-9. PubMed PMID: 15820941. Epub 2005/04/12. eng.

Adami J, Gridley G, Nyren O, Dosemeci M, Linet M, Glimelius B, et al. Sunlight and non-Hodgkin’s lymphoma: a population-based cohort study in Sweden. International journal of cancer Journal international du cancer. 1999 Mar 1;80(5):641-5. PubMed PMID: 10048959. Epub 1999/02/27. eng.

Diehl LF, Karnell LH, Menck HR. The American College of Sur- geons Commission on Cancer and the American Cancer Society. The National Cancer Data Base report on age, gender, treatment, and out- comes of patients with chronic lymphocytic leukemia. Cancer. 1999 Dec 15;86(12):2684-92. PubMed PMID: 10594864. Epub 1999/12/14. eng.

Gaidano G, Foa R, Dalla-Favera R. Molecular pathogenesis of chron- ic lymphocytic leukemia. J Clin Invest. 2012 Oct 1;122(10):3432-8. PubMed PMID: 23023714. Pubmed Central PMCID: PMC3461921. Epub 2012/10/02. eng.

Matutes E, Morilla R, Owusu-Ankomah K, Houlihan A, Catovsky D. The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disor- ders. Blood. 1994 Mar 15;83(6):1558-62. PubMed PMID: 8123845. Epub 1994/03/15. eng.

Goldin LR, Pfeiffer RM, Li X, Hemminki K. Familial risk of lym- phoproliferative tumors in families of patients with chronic lympho- cytic leukemia: results from the Swedish Family-Cancer Database. Blood. 2004 Sep 15;104(6):1850-4. PubMed PMID: 15161669. Epub 2004/05/27. eng.

Hodgson K, Ferrer G, Montserrat E, Moreno C. Chronic lympho- cytic leukemia and autoimmunity: a systematic review. Haematologica. 2011 May;96(5):752-61. PubMed PMID: 21242190. Pubmed Central PMCID: PMC3084923. Epub 2011/01/19. eng.

Kokhaei P, Choudhury A, Mahdian R, Lundin J, Moshfegh A, Oster- borg A, et al. Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL. Leukemia : official journal of the Leukemia Society of America, Leu- kemia Research Fund, UK. 2004 Nov;18(11):1810-5. PubMed PMID: 15385926. Epub 2004/09/24. eng.

Alfarano A, Indraccolo S, Circosta P, Minuzzo S, Vallario A, Zamar- chi R, et al. An alternatively spliced form of CD79b gene may account for altered B-cell receptor expression in B-chronic lymphocytic leu- kemia. Blood. 1999 Apr 1;93(7):2327-35. PubMed PMID: 10090943. Epub 1999/03/26. eng.

Shanafelt TD, Kay NE. Comprehensive management of the CLL patient: a holistic approach. Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program. 2007:324-31. PubMed PMID: 18024647. Epub 2007/11/21. eng.

Mozaheb Z, Hasanzadeh NazarAbadi MH, Aghaee MA. Chronic lymphocytic leukemia and prognostic factors. Asian Pacific journal of cancer prevention : APJCP. 2012;13(7):3009-13. PubMed PMID: 22994703. Epub 2012/09/22. eng.

Stilgenbauer S, Bullinger L, Lichter P, Dohner H. Genetics of chron- ic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2002 Jun;16(6):993-1007. PubMed PMID: 12040431. Epub 2002/06/01. eng.

Rodríguez-Vicente AE, Díaz MG, Hernández-Rivas JM. Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease. Cancer Genetics. 2013 3//;206(3):49-62.

Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Un- mutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999 Sep 15;94(6):1848-54. PubMed PMID: 10477713. Epub 1999/09/09. eng.

Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, et al. Ig V gene mutation status and CD38 expression as novel prognostic indica- tors in chronic lymphocytic leukemia. Blood. 1999 Sep 15;94(6):1840- 7. PubMed PMID: 10477712. Epub 1999/09/09. eng.

Bilous N, Abramenko I, Kryachok I, Bazyka D, Chumak A, Bebe- shko V. Significance of VH genes mutation status for prognosis of CLL patients. Exp Oncol. 2005 Dec;27(4):325-9. PubMed PMID: 16404355. Epub 2006/01/13. eng.

Messmer BT, Albesiano E, Messmer D, Chiorazzi N. The pattern and distribution of immunoglobulin VH gene mutations in chronic lymphocytic leukemia B cells are consistent with the canonical somatic hypermutation process. Blood. 2004 May1;103(9):3490-5. PubMed PMID: 14695232. Epub 2003/12/26. eng.

Chapman CJ, Wright D, Feizi H, Davis Z, Stevenson FK. VH gene analysis of Burkitt’s lymphoma in children from north western Iran. British journal of haematology. 1998;103(4):1116-23.

Farsangi MH, Jeddi-Tehrani M, Sharifian RA, Razavi SM, Khoshnoodi J, Rabbani H, et al. Analysis of the immunoglobulin heavy chain variable region gene expression in Iranian patients with chron- ic lymphocytic leukemia. Leuk Lymphoma. 2007 Jan;48(1):109-16. PubMed PMID: 17325854. Epub 2007/02/28. eng.

Hojjat-Farsangi M, Jeddi-Tehrani M, Razavi SM, Sharifian RA, Mellstedt H, Shokri F, et al. Immunoglobulin heavy chain variable re- gion gene usage and mutational status of the leukemic B cells in Ira- nian patients with chronic lymphocytic leukemia. Cancer science. 2009 Dec;100(12):2346-53. PubMed PMID: 19824994. Epub 2009/10/15. eng.

Shokri F, Mageed RA, Richardson P, Jefferis R. Modulation and high frequency expression of autoantibody-associated cross-reactive id- iotypes linked to the VHI subgroup in CD5-expressing B lymphocytes from patients with chronic lymphocytic leukaemia (B-CLL). Scandi- navian journal of immunology. 1993 Jun;37(6):673-9. PubMed PMID: 7686301. Epub 1993/06/01. eng.

Gharagozloo S, Sharifian RA, Mageed RA, Shokri F. Analysis of the expressed immunoglobulin variable region heavy chain gene prod- ucts in paraproteins from Iranian patients with multiple myeloma. Pa- thology oncology research : POR. 2000;6(3):185-90. PubMed PMID: 11033458. Epub 2000

IssueVol 5 No 4 (2013) QRcode
SectionOriginal Articles
Keywords
Chronic Lymphocytic Leukemia IGVH mutation Somatic Hypermutation Prognostic Factor Overall Survival

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Sadighi S, Jahanzad I, Mohagheghi MA, Shokrollahi M, Zendehdel K, Hojjat-Farsangi M, Kokhaei P. Retracted: Somatic Mutation in Immunoglobulin Gene Variable Region in Patients with Chronic Lymphoid Leukemia and its Influence on Patients’ Prognosis in Iran. Basic Clin Cancer Res. 2014;5(4):19-25.